Avalon GloboCare Corp.
ALBTNasdaq
$0.29
↓ -5.8%Jul 17 close · end-of-day
Price
1Y↓ -88.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.6M
Enterprise Value
$1.8M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$20.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-172.8%
ROIC
-61.5%
Debt / Equity
—
Net Cash
$775,995.00
Return 1Y
-87.7%
Company profile
Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.
- CEO
- David K. Jin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- New Jersey
Earnings
ALBT Q 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.50↓ -65.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.2M | $1.3M | $1.3M | — |
| Gross profit | $390,203.00 | $414,518.00 | $272,728.00 | — | — | — |
| Operating income | -$12.5M | -$8.8M | -$8.8M | -$15.8M | -$4.8M | -$7.6M |
| Net income | -$12.7M | -$9.1M | -$11.9M | -$16.7M | -$7.9M | -$18.3M |
| Diluted EPS | — | -$1.07 | -$1.28 | -$23.80 | -$8.44 | -$5.64 |
| Operating cash flow | -$7.5M | -$5.0M | -$7.0M | -$6.5M | -$4.7M | -$4.6M |
| Free cash flow | — | -$5.0M | -$7.0M | -$6.5M | — | — |
| Gross margin | 28.3% | 29.8% | 22.7% | — | — | — |
| Operating margin | -903.9% | -635.1% | -731.4% | -1254.6% | -363.1% | — |
| Net margin | -920.3% | -653.5% | -992.4% | -1330.5% | -592.7% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $327,887.00 | $345,159.00 | $345,769.00 | $349,800.00 | $350,406.00 | $350,099.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.5M | -$1.3M | -$1.2M | -$1.8M | -$3.9M | -$76,193.00 | -$1.8M | -$2.7M |
| Net income | -$2.1M | -$1.7M | -$2.7M | -$2.5M | -$13.5M | -$254,268.00 | -$2.1M | -$4.5M |
| Diluted EPS | -$2.85 | -$1.82 | -$1.91 | -$1.43 | -$6.22 | -$0.06 | $2.07 | -$0.50 |
| Operating cash flow | -$1.1M | -$1.9M | -$777,465.00 | -$1.7M | -$1.3M | -$1.4M | -$192,063.00 | -$2.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -458.8% | -367.9% | -354.0% | -510.4% | -1109.6% | -21.8% | — | — |
| Net margin | -650.2% | -486.5% | -788.0% | -709.6% | -3840.9% | -72.6% | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.